Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
16 November 2020Website:
http://www.puretechhealth.comNext earnings report:
29 August 2024Last dividends:
N/ANext dividends:
N/APrice
regular market | Wed, 03 Jul 2024 13:30:00 GMTDividend
Analysts recommendations
Institutional Ownership
PRTC Latest News
BOSTON--(BUSINESS WIRE)--PureTech Health: Results of the Tender Offer.
BOSTON--(BUSINESS WIRE)--Raju Kucherlapati, PhD, has been appointed Chair of the PureTech Board of Directors.
PureTech Health announces the initiation of a proposed tender offer of $100 million at 250 pence per Ordinary Share in Boston.
PureTech Health plc (NASDAQ:PRTC) Q4 2023 Earnings Conference Call on April 25, 2024 at 9:00 AM ET. Present on the call are Allison Mead Talbot, Bharatt Chowrira, Eric Elenko, and Chip Sherwood. Conference call participants include Miles Dixon from Peel Hunt and Lucy Codrington from Jefferies. Thank you for joining the PureTech Health 2023 Year End Financial Results Conference Call. Please note that this call is being recorded.
PureTech Health (PRTC) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
PureTech Health's founded entity, Karuna Therapeutics, has been successful in developing a therapeutic with an optimized profile. Karuna Therapeutics was acquired by BMY for $14 billion. PureTech's lead asset, LYT-100, may be a promising treatment for idiopathic pulmonary fibrosis (IPF) with a better tolerability profile compared to standard of care drugs.
PureTech Health PLC Sponsored ADR (PRTC) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Shares in PureTech Health (LSE:PRTC, NASDAQ:PRTC, OTC:PTCHF) PLC jumped 10% after it agreed a US$500mln royalty deal, US$100mln of which will be paid upfront. In the first half hour of trading the shares were up 21.49p at 224.49p.
PureTech Health (LSE:PRTC, NASDAQ:PRTC, OTC:PTCHF) PLC announced a lucrative royalty deal with Royalty Pharma for its KarXT drug, developed by Karuna Therapeutics. In response, Liberum, the corporate broker, has increased its target price for PureTech Health from 420p to 470p, reiterating its 'buy' recommendation.
What type of business is PureTech Health?
PureTech Health plc, a clinical-stage biotherapeutics company, discovers, develops, and commercializes medicines for inflammatory, fibrotic and immunological, intractable cancers, lymphatic and gastrointestinal, neurological and neuropsychological, and other diseases in the United States. The company offers KarXT targeting muscarinic acetylcholine receptors to treat schizophrenia and psychosis in Alzheimer's disease; a regenerative biology platform for androgenetic alopecia, epithelial ageing, and other medical conditions; an immunomodulation platform to treat chronic and acute inflammatory disorders; oral therapies based on defined consortia of bacteria is isolated from the human microbiome; and therapies to treat cognitive dysfunction associated with depression, multiple sclerosis, post COVID and ICU, and cancer related conditions. It also provides hematopoietic stem cell based therapies for patients with blood cancer; a voice-based technology platform to detect voice changes linked to health conditions; and a technology platform for the oral delivery of biologics, vaccines, and other drugs. In addition, the company is developing LYT-100 to treat lymphedema, and other lymphatic flow disorders; LYT-200, a IgG4 monoclonal antibody to target galectin-9; LYT-210 to treat solid tumors; Glyph, a synthetic lymphatic targeting chemistry platform; Orasome technology to enable the oral administration of macromolecule therapeutic payloads; meningeal lymphatics platform to treat Alzheimer's and Parkinson's diseases; and Alivio technology platform for inflammation-targeted disease immunomodulation. PureTech Health plc has collaboration and license agreements with Boehringer Ingelheim International GMBH; Eli Lilly and Company; Imbrium Therapeutics L.P.; and Shionogi & Co., Ltd. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.
What sector is PureTech Health in?
PureTech Health is in the Healthcare sector
What industry is PureTech Health in?
PureTech Health is in the Biotechnology industry
What country is PureTech Health from?
PureTech Health is headquartered in United States
When did PureTech Health go public?
PureTech Health initial public offering (IPO) was on 16 November 2020
What is PureTech Health website?
https://www.puretechhealth.com
Is PureTech Health in the S&P 500?
No, PureTech Health is not included in the S&P 500 index
Is PureTech Health in the NASDAQ 100?
No, PureTech Health is not included in the NASDAQ 100 index
Is PureTech Health in the Dow Jones?
No, PureTech Health is not included in the Dow Jones index
When does PureTech Health report earnings?
The next expected earnings date for PureTech Health is 29 August 2024